Cognitive disorders

BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease

Retrieved on: 
Friday, November 2, 2018
RTT, Medicine, Nervous system, Psychiatric diagnosis, Biology, Aging-associated diseases, Geriatrics, Cognitive disorders, Parkinson's disease, Tremor, Neurodegeneration, Dementia

Parkinson's disease is a progressive disease of the nervous system that is associated with reduced levels of dopamine in the brain.

Key Points: 
  • Parkinson's disease is a progressive disease of the nervous system that is associated with reduced levels of dopamine in the brain.
  • Tremor and movement disturbances are the pathological hallmarks of the disease, but it is also characterized by dementia, depression, sleep disturbance and other symptoms.
  • As the second most common neurodegenerative disease, after Alzheimer's disease, Parkinson's disease affects a large number of individuals and their families.
  • Patients with Parkinson's disease suffer from an extensive loss of nerve cells in a part of the brain associated with movement.

BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease

Retrieved on: 
Friday, November 2, 2018
RTT, Medicine, Nervous system, Psychiatric diagnosis, Biology, Aging-associated diseases, Geriatrics, Cognitive disorders, Parkinson's disease, Tremor, Neurodegeneration, Dementia

Parkinson's disease is a progressive disease of the nervous system that is associated with reduced levels of dopamine in the brain.

Key Points: 
  • Parkinson's disease is a progressive disease of the nervous system that is associated with reduced levels of dopamine in the brain.
  • Tremor and movement disturbances are the pathological hallmarks of the disease, but it is also characterized by dementia, depression, sleep disturbance and other symptoms.
  • As the second most common neurodegenerative disease, after Alzheimer's disease, Parkinson's disease affects a large number of individuals and their families.
  • Patients with Parkinson's disease suffer from an extensive loss of nerve cells in a part of the brain associated with movement.

Global Alzheimer's Disease Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares

Retrieved on: 
Tuesday, October 30, 2018
Medicine, Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, RTT, Dementia, Alzheimer's disease, Market share, Disease

The "Global Alzheimer's Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Alzheimer's Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Alzheimer's Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Alzheimer's Disease pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Alzheimer's Disease market size and drug sales.
  • The research is classified into following sections - Alzheimer's Disease overview with definitions, symptoms, etiology, diagnosis, treatment options; Alzheimer's Disease pipeline insights covering late stage clinical trials pipeline; Alzheimer's Disease prevalence trends by countries; Alzheimer's Disease market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Silicon Valley Philanthropist and Alzheimer's Association Build the Research Pipeline

Retrieved on: 
Tuesday, October 30, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Health, Neuroscience, Alzheimer's Association, Alzheimer's disease, Dementia, Alzheimer's Research UK, Cure Alzheimer's Fund

Since 2012, Part the Cloud has raised more than $29 million to invest in the Alzheimer's Association research grants.

Key Points: 
  • Since 2012, Part the Cloud has raised more than $29 million to invest in the Alzheimer's Association research grants.
  • These are "high risk" science projects that need seed funding as the researchers test their ideas and build initial supportive data.
  • Part the Cloud is a research funding effort from the Alzheimer's Association, the world's leading nonprofit funder of Alzheimer's and dementia research.
  • For more information, visit the Alzheimer's Association at alz.org
    The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research.

HKBU's New Nanomaterial Could Enable Early Detection and Diagnosis of Alzheimer's Disease

Retrieved on: 
Tuesday, October 30, 2018
Nervous system, Neuroscience, Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, RTT, Dementia, Alzheimer's disease, Blood–brain barrier

Researchers from Hong Kong Baptist University (HKBU) have discovered a new nanomaterial which could enable the early detection and diagnosis of Alzheimer's disease.

Key Points: 
  • Researchers from Hong Kong Baptist University (HKBU) have discovered a new nanomaterial which could enable the early detection and diagnosis of Alzheimer's disease.
  • Non-toxic and sensitive to detection, the new material can easily pass through the blood-brain barrier*, enabling clear imaging - and detection - of the protein plaques which cause Alzheimer's disease.
  • The new nanomaterial could also be used to monitor the progression of the disease and the effectiveness of potential drugs.
  • The early detection of these plaques could help speed up the diagnosis of Alzheimer's and enable people to receive treatment earlier.

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Retrieved on: 
Saturday, October 27, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Abnormal psychology, Alzheimer's disease, RTT, Biology

In addition, when moderate AD patients were analyzed by plasma exchange combination type, all three combinations achieved statistical significance for ADCS-ADL.

Key Points: 
  • In addition, when moderate AD patients were analyzed by plasma exchange combination type, all three combinations achieved statistical significance for ADCS-ADL.
  • This is the most significant development in the treatment of patients with moderate Alzheimer's disease in over 15 years," said Merc Boada, M.D., Ph.D., Director of Fundaci ACE.
  • The AMBAR study included 496 mild and moderate Alzheimer patients, randomized in three treatment groups and one control (placebo) group.
  • Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Retrieved on: 
Saturday, October 27, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Abnormal psychology, Alzheimer's disease, RTT, Medicine

- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients.

Key Points: 
  • - AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients.
  • This is the most significant development in the treatment of patients with moderate Alzheimer's disease in over 15 years," said Merc Boada, M.D., Ph.D., Director of Fundaci ACE.
  • The AMBAR study included 496 mild and moderate Alzheimer patients, randomized in three treatment groups and one control (placebo) group.
  • Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

US Alzheimer's Disease Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, And Market Shares

Retrieved on: 
Wednesday, October 24, 2018
Health, Medicine, Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Abnormal psychology, Alzheimer's disease, Clinical trial

US Alzheimer's Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Alzheimer's Disease pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.

Key Points: 
  • US Alzheimer's Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Alzheimer's Disease pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Alzheimer's Disease market size and drug sales.
  • The research is classified into following sections - Alzheimer's Disease overview with definitions, symptoms, etiology, diagnosis, treatment options; Alzheimer's Disease pipeline insights covering late stage clinical trials pipeline; Alzheimer's Disease prevalence trends by countries; Alzheimer's Disease market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Alzheimer's Disease pipeline: Find out the drugs in clinical trials for Alzheimer's Disease by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Alzheimer's Disease epidemiology: Find out the prevalence of Alzheimer's Disease in US; prevalence forecast to 2023
    Alzheimer's Disease products: Identify key products marketed and prescribed for Alzheimer's Disease by brand name, by molecule, by company, by branded / generic, in US
    Alzheimer's Disease market size: Find out the market size for Alzheimer's Disease drugs in US; Find out how the market advanced from 2014
    Alzheimer's Disease drugs sales forecast: Sales forecast for Alzheimer's Disease drugs to 2023 in US
    Alzheimer's Disease market share analysis: Find out the market shares of Alzheimer's Disease drugs and outlook in US
    Did you know that we also offer Custom Research?

Third Annual AFTD Benefit Draws Largest Attendance to Date, Raises over $1.9 Million, in Support of Frontotemporal Degeneration Research, Support and Awareness

Retrieved on: 
Tuesday, October 23, 2018
Cognitive disorders, Dementia, Psychiatry, Psychiatric diagnosis, Aphasias, Neuroscience, Learning disabilities, Alzheimer's disease, Medicine, Anna Wintour, Wintour

Frontotemporal degeneration causes irreversible changes to a person's language, movement, behavior and/or personality, while leaving long-term memory generally intact.

Key Points: 
  • Frontotemporal degeneration causes irreversible changes to a person's language, movement, behavior and/or personality, while leaving long-term memory generally intact.
  • Currently there are no approved treatments for FTD, which affects more than 60,000 in the United States.
  • About AFTD's 2018 Hope Rising Benefit: AFTD thanks benefit chair Donald E. Newhouse, and benefit co-chairs Anna Wintour and David Zaslav.
  • A study commissioned by AFTD and published inNeurology(now available online ) found FTD's average annual costs to be nearly double those of Alzheimer's disease.

Alzheimer's Association Statement on Justice Sandra Day O'Connor's Announcement of Dementia Diagnosis

Retrieved on: 
Tuesday, October 23, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Neuroscience, Medicine, Dementia, Justice O'Connor, Sandra Day O'Connor, O'Connor, Alzheimer's disease

CHICAGO, Oct. 23, 2018 /PRNewswire/ -- Former Supreme Court Justice Sandra Day O'Connor continues to demonstrate her leadership in the face of adversity, today bravely announcing her diagnosis of dementia, possibly Alzheimer's.

Key Points: 
  • CHICAGO, Oct. 23, 2018 /PRNewswire/ -- Former Supreme Court Justice Sandra Day O'Connor continues to demonstrate her leadership in the face of adversity, today bravely announcing her diagnosis of dementia, possibly Alzheimer's.
  • In all aspects of her life Justice O'Connor has been a transparent leader, and being forthcoming about her diagnosis is another demonstration of this.
  • In 2005, as John was in decline from the disease, Justice O'Connor stepped down from the Supreme Court to spend more time with him.
  • Since her husband's diagnosis with Alzheimer's disease, Justice O'Connor has been an advocate for caregivers and people living with the disease.